Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control
Completed
This study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from the blood of adults with certain blood cancers (leukemia and lymphoma) that had come back or not responded to treatment. The main goals were to see if the cells could be succe…
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated May 17, 2026 06:44 UTC